Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISA 2022 | Improving the outcomes of patients with AL amyloidosis and cardiac involvement

Panagiota-Efstathia Nikolaou • 6 Sep 2022
ISA 2022
Amyloidosis Rare Diseases

Panagiota-Efstathia Nikolaou, PhD, National and Kapodistrian University of Athens, Athens, Greece, shares her perspectives on optimizing the outcomes of patients with AL amyloidosis with cardiac involvement. Dr Nikolaou highlights the importance of multi-target therapies and multidisciplinary treatment approaches. This interview took place at the 2022 International Symposium on Amyloidosis (ISA) held in Heidelberg, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Panagiota-Efstathia Nikolaou

1:14
Targeting ER stress to preserve cardiac function in patients with AL amyloidosis
Panagiota-Efstathia Nikolaou • 6 Sep 2022
2:11
The cardiotoxicity of full-length light chains in patients with cardiac AL amyloidosis
Panagiota-Efstathia Nikolaou • 6 Sep 2022

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
1:18
Autologous gene editing using the CRISPR system to treat primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
0:58
Hematological manifestations associated with primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals